Last reviewed · How we verify
Buphenin — Competitive Intelligence Brief
unknown
buphenine
Adrenergic receptor alpha-1
Hematology
Live · refreshed every 30 min
Target snapshot
Buphenin (buphenine). Buphenine works by stimulating the alpha-1 adrenergic receptors, which helps to constrict blood vessels and improve blood flow.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Buphenin TARGET | buphenine | unknown | buphenine | Adrenergic receptor alpha-1 | ||
| Levonordefrin | corbadrine | Eastman Kodak | marketed | corbadrine | Alpha-1D adrenergic receptor, Adrenergic receptor alpha-2, Adrenergic receptor alpha-1 | 1960-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (buphenine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Buphenin CI watch — RSS
- Buphenin CI watch — Atom
- Buphenin CI watch — JSON
- Buphenin alone — RSS
- Whole buphenine class — RSS
Cite this brief
Drug Landscape (2026). Buphenin — Competitive Intelligence Brief. https://druglandscape.com/ci/buphenine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing